Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:APTO
- CUSIP: N/A
- Web: www.aptose.com
Capitalization:- Market Cap: $33.28 million
- Outstanding Shares: 21,753,000
Average Prices:- 50 Day Moving Avg: $1.29
- 200 Day Moving Avg: $1.14
- 52 Week Range: $0.78 - $3.20
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.22
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.43 per share
- Price / Book: 3.56
Profitability:- EBIDTA: ($14,230,000.00)
- Return on Equity: -174.74%
- Return on Assets: -146.38%
Debt:- Current Ratio: 5.33%
- Quick Ratio: 5.33%
Misc:- Average Volume: 500,798 shs.
- Beta: 1.62
- Short Ratio: 1.78
Frequently Asked Questions for Aptose Biosciences (NASDAQ:APTO)
What is Aptose Biosciences' stock symbol?
Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."
How were Aptose Biosciences' earnings last quarter?
Aptose Biosciences, Inc. (NASDAQ:APTO) posted its quarterly earnings data on Tuesday, March, 29th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.10. View Aptose Biosciences' Earnings History.
Where is Aptose Biosciences' stock going? Where will Aptose Biosciences' stock price be in 2017?
5 brokerages have issued twelve-month price targets for Aptose Biosciences' stock. Their forecasts range from $7.00 to $12.00. On average, they anticipate Aptose Biosciences' stock price to reach $9.00 in the next year. View Analyst Ratings for Aptose Biosciences.
What are analysts saying about Aptose Biosciences stock?
Here are some recent quotes from research analysts about Aptose Biosciences stock:
- 1. Canaccord Genuity analysts commented, "CATB reported 3/31 cash of $38.5MM, sufficient to fund operations into Q2:18." (5/12/2017)
- 2. According to Zacks Investment Research, "Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. " (11/17/2016)
Who are some of Aptose Biosciences' key competitors?
Some companies that are related to Aptose Biosciences include CASI Pharmaceuticals (CASI), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Regulus Therapeutics (RGLS), BioLineRx (BLRX), Sunesis Pharmaceuticals (SNSS), ReNeuron Group Plc (RENE), OvaScience (OVAS), Fibrocell Science (FCSC), Senomyx (SNMX), Prima BioMed Ltd (PBMD), Threshold Pharmaceuticals (THLD), Bio-Path Holdings (BPTH), Burcon NutraScience Corp (BUR), AEterna Zentaris (AEZS), Cleveland BioLabs (CBLI), Scancell Holdings Plc (SCLP) and Nabriva Therapeutics AG (NBRV).
Who are Aptose Biosciences' key executives?
Aptose Biosciences' management team includes the folowing people:
- William Glenn Rice, Chairman of the Board, President, Chief Executive Officer
- Gregory Kwok Lee Chow, Chief Financial Officer, Senior Vice President
- Denis R. Burger Ph.D., Independent Director
- Erich M. Platzer M.D., Ph.D., Independent Director
- Bradley Thompson, Independent Director
- Mark D. Vincent M.D., Independent Director
- Warren Whitehead, Independent Director
How do I buy Aptose Biosciences stock?
Shares of Aptose Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aptose Biosciences' stock price today?
One share of Aptose Biosciences stock can currently be purchased for approximately $1.53.
MarketBeat Community Rating for Aptose Biosciences (NASDAQ APTO)MarketBeat's community ratings are surveys of what our community members think about Aptose Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Aptose Biosciences (NASDAQ:APTO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.60) |
| Consensus Price Target: | $9.00 (488.24% upside) |
Analysts' Ratings History for Aptose Biosciences (NASDAQ:APTO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/8/2017 | HC Wainwright | Initiated Coverage | Hold | | High |  |
| 6/8/2017 | Rodman & Renshaw | Initiated Coverage | Neutral -> Neutral | | High | |
| 5/12/2017 | Canaccord Genuity | Reiterated Rating | Buy | $7.00 | Low | |
| 11/16/2016 | Royal Bank Of Canada | Lower Price Target | Outperform | $18.00 -> $12.00 | N/A | |
| 10/14/2016 | Roth Capital | Reiterated Rating | Buy | $8.00 | N/A | |
| 6/9/2016 | Oppenheimer Holdings, Inc. | Reiterated Rating | Buy | | N/A | |
(Data available from 7/26/2015 forward)
Earnings History for Aptose Biosciences (NASDAQ:APTO)Earnings History by Quarter for Aptose Biosciences (NASDAQ APTO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 3/29/2016 | Q415 | ($0.28) | ($0.38) | | | View | N/A | |
| 11/10/2015 | Q315 | ($0.33) | ($0.27) | | | View | N/A | |
| 8/4/2015 | Q215 | ($0.31) | ($0.22) | | | View | N/A | |
| 3/3/2015 | Q4 2014 | ($0.31) | ($0.25) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Aptose Biosciences (NASDAQ:APTO)Current Year EPS Consensus Estimate: $-1.17 EPS
Next Year EPS Consensus Estimate: $-0.69 EPS
Dividend History for Aptose Biosciences (NASDAQ:APTO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Aptose Biosciences (NASDAQ:APTO)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Aptose Biosciences (NASDAQ:APTO)
Latest Headlines for Aptose Biosciences (NASDAQ:APTO)
| Source: |
|
| Date | Headline |
|---|
 | Reviva Pharmaceuticals Announces Addition of a New Member to its Board of Directors
www.businesswire.com - July 23 at 1:57 AM |
 | Aptose Biosciences, Inc. (APTO) Expected to Post Earnings of -$0.18 Per Share
www.americanbankingnews.com - July 13 at 8:29 AM |
 | Prostate Cancer Pipeline H1 2017 Therapeutic Key Players 3-V Biosciences Inc, 4SC AG, Actinium Pharmaceuticals ... - PR Newswire (press release)
www.prnewswire.com - July 11 at 3:22 PM |
| Aptose Biosciences, Inc. (APTO) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - July 4 at 10:02 AM |
| Analysts Anticipate Aptose Biosciences, Inc. (APTO) Will Post Earnings of -$0.18 Per Share
www.americanbankingnews.com - June 19 at 9:42 AM |
| Aptose Biosciences Inc (APTO) Coverage Initiated by Analysts at HC Wainwright
www.americanbankingnews.com - June 11 at 9:02 AM |
 | Benzinga's Top Upgrades, Downgrades For June 8, 2017 - Benzinga
www.benzinga.com - June 9 at 2:21 AM |
| Aptose Biosciences Inc (APTO) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 8 at 9:06 AM |
| Aptose Biosciences Inc (APTO) Coverage Initiated by Analysts at Rodman & Renshaw
www.americanbankingnews.com - June 8 at 7:38 AM |
 | Aptose Biosciences Announces Results of Annual Meeting of Shareholders - GlobeNewswire (press release)
globenewswire.com - June 6 at 8:41 PM |
 | Form 6-K Aptose Biosciences Inc. For: May 11 - StreetInsider.com
www.streetinsider.com - May 12 at 4:10 PM |
| Aptose Biosciences Inc (APTO) Receives Buy Rating from Canaccord Genuity
www.americanbankingnews.com - May 12 at 4:05 PM |
 | Investor Network: Aptose Biosciences Inc. to Host Earnings Call
finance.yahoo.com - May 12 at 2:04 AM |
| Aptose Reports Results for the First Quarter Ended March 31, 2017
finance.yahoo.com - May 12 at 2:04 AM |
| Aptose Reports Results for the First Quarter Ended March 31, 2017 - GlobeNewswire (press release)
globenewswire.com - May 11 at 9:03 PM |
| Preclinical Data on Aptose Biosciences FLT3/BTK Inhibitor CG'806 Presented at AACR Hematologic Malignancies ... - GlobeNewswire (press release)
globenewswire.com - May 8 at 8:34 PM |
| Aptose Biosciences Inc (APTO) Sees Significant Growth in Short Interest
www.americanbankingnews.com - May 8 at 8:52 AM |
| Aptose Biosciences (APTO) Receiving Favorable Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 29 at 9:56 AM |
| Aptose Biosciences (APTO) Receives Media Impact Score of 0.56
www.americanbankingnews.com - April 26 at 11:40 AM |
| Aptose To Release First Quarter Ended March 31, 2017 Financial Results and Hold Conference Call on May 11, 2017 - Yahoo Finance
finance.yahoo.com - April 25 at 3:34 PM |
| Form 6-K Aptose Biosciences Inc. For: Apr 25 - StreetInsider.com - StreetInsider.com
www.streetinsider.com - April 25 at 3:34 PM |
| Aptose Biosciences to Participate at the Bloom Burton & Co. Healthcare Investor Conference 2017
finance.yahoo.com - April 25 at 10:12 AM |
| Aptose To Release First Quarter Ended March 31, 2017 Financial Results and Hold Conference Call on May 11, 2017
finance.yahoo.com - April 24 at 10:41 AM |
| Aptose Biosciences to Present CG'806 Data at AACR Hematologic Malignancies Meeting - GlobeNewswire (press release)
www.globenewswire.com - April 20 at 1:42 AM |
| Aptose Biosciences to Present CG'806 Data at AACR Hematologic ... - GlobeNewswire (press release)
globenewswire.com - April 19 at 3:38 PM |
| Aptose Biosciences to Present CG'806 Data at AACR Hematologic Malignancies Meeting
feeds.benzinga.com - April 19 at 8:58 AM |
| Aptose Biosciences to Present CG’806 Data at AACR Hematologic Malignancies Meeting
finance.yahoo.com - April 19 at 8:32 AM |
| Aptose Biosciences (APTO) Earns Daily Coverage Optimism Score of 0.31
www.americanbankingnews.com - April 15 at 9:45 AM |
 | Aptose Reports Fourth Quarter and Year End 2016 Results
us.rd.yahoo.com - March 28 at 8:37 PM |
| How These Biotech Stocks are Faring? -- Actinium Pharma, Eleven Biotherapeutics, Neuralstem, and Aptose Biosciences - PR Newswire (press release)
www.prnewswire.com - March 27 at 8:12 AM |
| Aptose Biosciences (APTO) Announces Planned Departure of CBO Avanish Vellanki - StreetInsider.com
www.streetinsider.com - March 27 at 8:12 AM |
 | Aptose Biosciences (APTO) Presents At Cowen and Company 37th Annual Health Care Conference
seekingalpha.com - March 9 at 3:58 PM |
| Aptose to Participate in Upcoming Investor Conferences
feeds.benzinga.com - March 2 at 7:54 AM |
 | Aptose Biosciences to Present at Canaccord Genuity Rare Disease Biopharma 1x1 Day - Nasdaq
www.nasdaq.com - February 2 at 3:38 PM |
| Aptose Biosciences to Present at Canaccord Genuity Rare Disease Biopharma 1x1 Day
finance.yahoo.com - February 2 at 3:38 PM |
 | Aptose Delays Lead Cancer Drug Development (APTO)
www.investopedia.com - January 27 at 4:25 PM |
| Aptose Shifts Focus, Delays Cancer Drug Development
www.investopedia.com - January 27 at 4:25 PM |
| Aptose Bio (APTO) to Prioritize Development of CG'806 and Temporarily Delay Clinical Activities with APTO-253
www.streetinsider.com - January 23 at 8:50 PM |
| 7:02 am Aptose Biosciences will temporarily delay clinical activities with APTO-253 in order to elucidate the cause of recent manufacturing setbacks related to the intravenous formulation of APTO-253
us.rd.yahoo.com - January 23 at 8:50 PM |
| Form 6-K Aptose Biosciences Inc. For: Jan 23 - StreetInsider.com
www.streetinsider.com - January 23 at 3:40 PM |
Aptose Biosciences (APTO) Chart for Wednesday, July, 26, 2017
